Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Back to Forecasting
LLY Forecast Markets
Eli Lilly and Company
8
Active Markets
58%
Avg Probability
All Markets
8 markets
Will the FDA approve orforglipron (Lilly's oral GLP-1) by June 30, 2026?
84%
Likely Yes
95% agreement
Jul 15, 2026
IG: 0.80
Will the court deny Lilly's summary judgment motion in MDL 3094 (tirzepatide litigation), allowing claims to proceed to trial?
67%
Likely Yes
94% agreement
Sep 30, 2026
IG: 0.64
Will Lilly maintain above 55% U.S. incretin prescription share through H1 2026?
80%
Likely Yes
94% agreement
Aug 15, 2026
IG: 0.64
Will Lilly report that Medicare/government channel tirzepatide volume growth exceeds the pricing discount impact in Q2 2026?
48%
Likely No
93% agreement
Aug 15, 2026
IG: 0.64
Will Lilly report positive pivotal Phase 3 results for retatrutide (triple agonist) by December 31, 2026?
67%
Likely Yes
94% agreement
Jan 31, 2027
IG: 0.48
Will Novo Nordisk's CagriSema demonstrate superior weight loss to tirzepatide in head-to-head or cross-trial comparison by December 31, 2026?
14%
Likely No
94% agreement
Jan 31, 2027
IG: 0.48
Will any top-3 PBM (CVS Caremark, Express Scripts, OptumRx) exclude tirzepatide from preferred formulary status for 2027?
24%
Likely No
91% agreement
Dec 31, 2026
IG: 0.48
Will Lilly's FY 2026 gross margin remain above 80%?
78%
Likely Yes
94% agreement
Feb 28, 2027
IG: 0.36
Resolution Timeline
Aug 15, 2026
Will Lilly maintain above 55% U.S. incretin prescription share through H1 2026?Prediction: 80%
Jan 31, 2027
Will Lilly report positive pivotal Phase 3 results for retatrutide (triple agonist) by December 31, 2026?Prediction: 67%